EP1240201A4 - Oxidierte apolipoproteine und verfahren zu deren anwendung - Google Patents

Oxidierte apolipoproteine und verfahren zu deren anwendung

Info

Publication number
EP1240201A4
EP1240201A4 EP00979269A EP00979269A EP1240201A4 EP 1240201 A4 EP1240201 A4 EP 1240201A4 EP 00979269 A EP00979269 A EP 00979269A EP 00979269 A EP00979269 A EP 00979269A EP 1240201 A4 EP1240201 A4 EP 1240201A4
Authority
EP
European Patent Office
Prior art keywords
methods
apolipoproteins
oxidized
oxidized apolipoproteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00979269A
Other languages
English (en)
French (fr)
Other versions
EP1240201A1 (de
Inventor
Roland Stocker
Xing Li Wang
David Wilcken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heart Research Institute Ltd
Original Assignee
Heart Research Institute Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Research Institute Ltd filed Critical Heart Research Institute Ltd
Publication of EP1240201A1 publication Critical patent/EP1240201A1/de
Publication of EP1240201A4 publication Critical patent/EP1240201A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP00979269A 1999-11-26 2000-11-27 Oxidierte apolipoproteine und verfahren zu deren anwendung Withdrawn EP1240201A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ429399 1999-11-26
AUPQ4293A AUPQ429399A0 (en) 1999-11-26 1999-11-26 Oxidized apolipoproteins and methods of use
PCT/AU2000/001463 WO2001038395A1 (en) 1999-11-26 2000-11-27 Oxidized apolipoproteins and methods of use

Publications (2)

Publication Number Publication Date
EP1240201A1 EP1240201A1 (de) 2002-09-18
EP1240201A4 true EP1240201A4 (de) 2004-03-17

Family

ID=3818435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00979269A Withdrawn EP1240201A4 (de) 1999-11-26 2000-11-27 Oxidierte apolipoproteine und verfahren zu deren anwendung

Country Status (6)

Country Link
EP (1) EP1240201A4 (de)
JP (1) JP2003514918A (de)
AU (1) AUPQ429399A0 (de)
CA (1) CA2392355A1 (de)
NZ (1) NZ519040A (de)
WO (1) WO2001038395A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10035352A1 (de) 2000-07-20 2002-01-31 Zlb Bioplasma Ag Bern Verfahren zur Behandlung von instabiler Angina pectoris
US20040266660A1 (en) 2001-08-20 2004-12-30 Alphonse Hubsch Hdl for the treatment of stroke and other ischemic conditions
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
AU2011235920B2 (en) * 2003-12-05 2013-05-16 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
AU2004296829A1 (en) * 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US7749729B2 (en) 2004-07-19 2010-07-06 University Of Washington Methods for assessing the risk for development of cardiovascular disease
WO2006020498A2 (en) 2004-08-11 2006-02-23 The Cleveland Clinic Foundation Therapeutic agents and methods for cardiovascular disease
CN102784396B (zh) * 2004-11-09 2015-07-29 希尔氏宠物营养品公司 抗氧化剂用于基因调节的用途
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) * 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2012097420A1 (pt) * 2011-01-19 2012-07-26 Peixoto Eduardo Motta Alves Composição farmacêutica para tratamento de patologia induzida por estresse oxi dativo e uso da mesma
CN110082452B (zh) * 2019-05-23 2022-04-05 南京生命能科技开发有限公司 一种偶氮二异丁脒二盐酸盐检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009363A1 (fr) * 1993-09-29 1995-04-06 Yamasa Corporation Procede de titrage de lipoproteine oxydee et applications de ce procede

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PANZENBOECK UTE ET AL: "Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 47, 21 November 1997 (1997-11-21), pages 29711 - 29720, XP002267254, ISSN: 0021-9258 *
See also references of WO0138395A1 *
SIGALOV A B ET AL: "Enzymatic repair of oxidative damage to human apolipoprotein A-I", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 433, no. 3, 21 August 1998 (1998-08-21), pages 196 - 200, XP004258376, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
CA2392355A1 (en) 2001-05-31
WO2001038395A1 (en) 2001-05-31
JP2003514918A (ja) 2003-04-22
NZ519040A (en) 2004-02-27
AUPQ429399A0 (en) 1999-12-23
EP1240201A1 (de) 2002-09-18

Similar Documents

Publication Publication Date Title
GB2374100B (en) Underreamer and method of use
HK1043613A1 (zh) 微纖維及其製造方法
PL350822A1 (en) Disposable wiper-cloth and method of making same
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
HK1047432A1 (en) Hemisynthetic method and new compounds
EP1223932A4 (de) Verbindungen und verfahren
EP1146790A4 (de) Verbindungen und verfahren
AU6028598A (en) Non-iron metalloporphyrins and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
EP1183030A4 (de) Verfahren zur herstellung und ihre verwenung von n-desmethylzopiclone
AU4717301A (en) Catheter assembly and method of use
PL350826A1 (en) Disposable wiper-cloth and method of making same
SG108253A1 (en) Self-adhesive tape and method of use thereof
EP1240201A4 (de) Oxidierte apolipoproteine und verfahren zu deren anwendung
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
GB9819898D0 (en) New vaccine and method of use
GB0022710D0 (en) Dispenser and method of use
GB2367103B (en) Connector and method of use of the connector
HUP0104723A3 (en) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use
EP1263935A4 (de) Scytonemin und methoden seiner verwendung
IL134210A0 (en) Use of transcription factor brn-3a
HK1041878A1 (zh) 二羥吡啶化合物和其用作鉀通道開放劑的用途
PL350963A1 (en) Use of arylalkanoylpyridazines
GB0021915D0 (en) Creating and managing E-receipts
AU6405199A (en) Glutaraldehyde modified chemotherapeutic agents and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020626

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/775 A

Ipc: 7A 61K 38/17 B

A4 Supplementary search report drawn up and despatched

Effective date: 20040130

17Q First examination report despatched

Effective date: 20050308

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050719